Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q2 FY19 results · Jul–Sep 2018
Ajanta Pharma reported revenue from operations of ₹544.11 crore and net profit of ₹125.39 crore for Q2 FY19 (Jul–Sep 2018), on a consolidated basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 544.11 | — | — | 510.99 | +6.5% |
| Other income | 15.24 | — | — | 8.13 | +87.5% |
| Total income | 559.35 | — | — | 519.12 | +7.7% |
| Profit before tax | 163.84 | — | — | 148.28 | +10.5% |
| Net profit for the period | 125.39 | — | — | 105.79 | +18.5% |
| EPS, basic (₹) | 14.25 | — | — | 12.02 | +18.6% |
| Net margin (%) | 23.0 | — | 20.7 |
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 465.29 | — | — | 441.95 | +5.3% |
| Other income | 16.93 | — | — | 69.06 | −75.5% |
| Total income | 482.22 | — | — | 511.01 | −5.6% |
| Profit before tax | 141.98 | — | — | 193.36 | −26.6% |
| Net profit for the period | 104.10 | — | — | 150.82 | −31.0% |
| EPS, basic (₹) | 11.83 | — | — | 17.14 | −31.0% |
| Net margin (%) | 22.4 | — | 34.1 |
Consolidated
- Filed with BSE
- 01 Nov 2018, 13:10 IST
- Board meeting
- 31 Oct 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Nov 2018, 13:10 IST
- Board meeting
- 31 Oct 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE